6 terminated, 4 active not recruiting, 2 completed, 1 recruiting. 15 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Terminated 6, Active not recruiting 4, Completed 2, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 6 | Terminated 3, Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow Criterium, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer Fruquintinib+ Lonsurf (trifluridine and tipiracil), Fruquintinib - Colorectal Cancer | Phase 2 | Recruiting | Criterium, Inc. | 120 | 2025-10-27 | 2026-10-15 |
| Tucatinib+Trastuzumab+Eribulin in HER2+ MBC Tucatinib, Eribulin, Trastuzumab - Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer | Phase 2 | Active not recruiting | Criterium, Inc. | 17 | 2024-01-30 | 2026-07-10 |
| Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. Alpelisib, Tucatinib, Fulvestrant - HER2-positive Metastatic Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Criterium, Inc. | 40 | 2022-08-25 | 2026-03-16 |
| Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer Evorpacept (ALX148), Cetuximab, Pembrolizumab - Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | Terminated | University of Colorado, Denver | 19 | 2022-07-28 | 2026-09-03 |
| A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis AMG 510, MVASI - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Criterium, Inc. | 2022-06-15 | 2023-10-18 | |
| CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC Tepotinib - Advanced Non-Small Cell Lung Cancer With MET Mutations | Phase 1 / Phase 2 | Terminated | Criterium, Inc. | 2 | 2022-05-25 | 2023-10-18 |
| Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer Abemaciclib, Elacestrant - Breast Cancer | Phase 1 / Phase 2 | Terminated | Criterium, Inc. | 5 | 2022-04-21 | 2026-03-31 |
| Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer Cabozantinib, Nivolumab - Colorectal Adenocarcinoma, Colon Cancer | Phase 2 | Active not recruiting | University of Colorado, Denver | 48 | 2021-06-23 | 2026-03-31 |
| DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) Palbociclib, Fulvestrant, Adjuvant Therapy - Breast Cancer | Phase 2 | Active not recruiting | Criterium, Inc. | 70 | 2021-02-09 | 2026-10-15 |
| FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer Oxaliplatin - Colorectal Cancer Metastatic | Phase 2 | Unknown | Criterium, Inc. | 27 | 2019-12-02 | 2023-07-27 |
| Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer Tucatinib in Combination with Palbociclib and Letrozole - Breast Cancer | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 42 | 2017-11-27 | 2023-11-13 |
| Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors brigatinib - Non-Small Cell Lung Cancer | Phase 2 | Terminated | Criterium, Inc. | 32 | 2017-03-09 | 2023-01-26 |
| Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Nab paclitaxel, Gemcitabine - Pancreatic Cancer, Pancreatic Adenocarcinoma | Phase 2 | Completed | Academic Thoracic Oncology Medical Investigators Consortium | 48 | 2016-12-30 | 2025-07-01 |
| Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies ceritinib - Colorectal Adenocarcinoma, Cholangiocarcinoma | Phase 2 | Terminated | Criterium, Inc. | 4 | 2015-12-01 | 2018-04-02 |
| A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Carfilzomib, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Criterium, Inc. | 136 | 2011-11-01 | 2022-08-01 |
Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Adenocarcinoma Of Esophagus (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Multiple Myeloma (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1)
tucatinib (3) · Fulvestrant (2) · palbociclib (2) · ALX148 (1) · Albumin-Bound Paclitaxel (1) · Alpelisib (1) · Bevacizumab (1) · Calcium Dobesilate (1) · Cetuximab (1) · Chemotherapy, Adjuvant (1) · Dexamethasone (1) · Gemcitabine (1) · HMPL-013 (1) · Irinotecan (1) · Letrozole (1)
United States (15)
Wells Messersmith, MD (2) · Alexis Leal, MD (1) · Brian GM Durie, MD (1) · Christopher Lieu, MD (1) · David R Camidge, MD, PhD (1) · Elena Shagisultanova, MD (1) · Elena Shagisultanova, MD, PhD (1) · Hank Kaplan, MD (1) · Howard Hochster, MD (1) · Jatin Shah, MD (1) · Lajos Pusztai, MD (1) · Peter Kabos, MD (1) · Tejas Patil, MD (1) · Thomas Stinchcombe, MD (1) · Wade Iams, MD, MSCI (1)
PMID 26384354, PMID 33039599, PMID 34728571, PMID 36101520, PMID 37363965, PMID 40972532, PMID 41171165, PMID 42610703
P30CA046934 (1)